Company intelligence / Profile preview

IntraDerm Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

IntraDerm launched with a portfolio of Microcyn-based dermatology products that have demonstrated efficacy in clinical studies and daily use for resolving skin dermatoses, managing scars, reducing pain and itch. Multiple products are commercialized in the US and Europe. Clinical results highlight reduction in infection risk, inflammation, pain/itch relief, and improved scar outcomes.

Therapeutic areas: Dermatology
Modalities: Small moleculeBiologicDevice-based drug delivery
Industry: Biotech

Drug pipeline

1 asset

OLX101A

Phase 2

Indications: Hypertrophic scar, Keloids

Beyond the preview

Go deeper on IntraDerm Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntraDerm Pharmaceuticals.

Explore the full profile